{"id":"hydrogel-vehicle","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108661","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hydrogels are cross-linked polymer networks that absorb and retain water, creating a gel-like consistency. They function as passive delivery vehicles that can be formulated with active pharmaceutical ingredients to provide sustained or controlled release, improve skin penetration, and enhance patient compliance through improved formulation aesthetics and reduced irritation.","oneSentence":"A hydrogel vehicle serves as an inert pharmaceutical delivery matrix designed to control drug release and improve topical or local drug bioavailability.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:23:22.923Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Topical drug delivery vehicle for dermatological applications"}]},"trialDetails":[{"nctId":"NCT06568627","phase":"PHASE3","title":"A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)","status":"RECRUITING","sponsor":"MediWound Ltd","startDate":"2025-06-01","conditions":"Venous Leg Ulcer (VLU)","enrollment":216},{"nctId":"NCT04225611","phase":"PHASE1, PHASE2","title":"Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema","status":"RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2021-03-15","conditions":"Cystoid Macular Edema","enrollment":6},{"nctId":"NCT04569409","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Wagner Grade 2 Foot Ulcers.","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2020-07-14","conditions":"Diabetic Foot Ulcer","enrollment":104},{"nctId":"NCT06855745","phase":"PHASE2","title":"Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.","status":"RECRUITING","sponsor":"Alphyn Biologics","startDate":"2025-03-25","conditions":"Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis","enrollment":72},{"nctId":"NCT06957197","phase":"PHASE3","title":"Clinical Comparison of Xenograft With Hydrogel Versus Xenograft Alone in the Socket Preservation After Tooth Extraction: A Randomized Controlled Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Cairo University","startDate":"2025-09-22","conditions":"Socket Perservation","enrollment":26},{"nctId":"NCT01368146","phase":"PHASE1","title":"Human Repeat Insult Patch Test of Wound Dressings","status":"COMPLETED","sponsor":"Covalon Technologies Inc.","startDate":"2011-03","conditions":"Skin Sensitization","enrollment":216},{"nctId":"NCT03461354","phase":"NA","title":"MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer","status":"TERMINATED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-04-09","conditions":"Mucositis Oral, Head and Neck Cancer","enrollment":49},{"nctId":"NCT03754465","phase":"PHASE2","title":"Clinical Study of ALLO-ASC-SHEET in Subjects with Diabetic Foot Ulcers","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2019-01-02","conditions":"Diabetic Foot Ulcer","enrollment":66},{"nctId":"NCT06690177","phase":"PHASE2","title":"Clinical Study to Evaluate the Safety and the Efficacy of EscharEx Drug Product (EX-03 Formulation) and Its Placebo Compared to Collagenase, Non-surgical Standard of Care, in Patients With Venous Leg Ulcers","status":"NOT_YET_RECRUITING","sponsor":"MediWound Ltd","startDate":"2025-04-30","conditions":"Venus Leg Ulcers","enrollment":45},{"nctId":"NCT05157958","phase":"PHASE2","title":"Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa","status":"RECRUITING","sponsor":"Anterogen Co., Ltd.","startDate":"2023-05-01","conditions":"Dystrophic Epidermolysis Bullosa","enrollment":6},{"nctId":"NCT04362670","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-CSI in Subjects With Dry Eye Disease.","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2020-04-23","conditions":"Dry Eye Disease","enrollment":153},{"nctId":"NCT03370874","phase":"PHASE3","title":"Clinical Study to Evaluate Efficacy and Safety of ALLO-ASC-DFU in Patients With Diabetic Foot Ulcers.","status":"COMPLETED","sponsor":"Anterogen Co., Ltd.","startDate":"2018-06-27","conditions":"Diabetic Foot Ulcer","enrollment":150},{"nctId":"NCT04497805","phase":"PHASE2","title":"Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers","status":"UNKNOWN","sponsor":"Anterogen Co., Ltd.","startDate":"2020-09-08","conditions":"Diabetic Foot Ulcer","enrollment":64},{"nctId":"NCT04747977","phase":"PHASE2","title":"To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2021-02-12","conditions":"Dry Eye","enrollment":172},{"nctId":"NCT03588130","phase":"PHASE2","title":"A Study to Evaluate the Safety and the Efficacy of EscharEx (EX-02 Formulation) in Debridement of Venous Leg Ulcers","status":"COMPLETED","sponsor":"MediWound Ltd","startDate":"2019-12-02","conditions":"Venous Leg Ulcer","enrollment":120},{"nctId":"NCT01666210","phase":"PHASE2","title":"Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2012-10","conditions":"Ocular Inflammation and Pain","enrollment":60},{"nctId":"NCT04995354","phase":"PHASE2, PHASE3","title":"Efficacy of EGF-loaded Self Healing Gel in Treatment of Oral Mucositis","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-06-01","conditions":"Oral Mucositis","enrollment":90},{"nctId":"NCT02034019","phase":"PHASE3","title":"Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery","status":"COMPLETED","sponsor":"Ocular Therapeutix, Inc.","startDate":"2014-02","conditions":"Post Ocular Surgical Inflammation and Pain","enrollment":247},{"nctId":"NCT03700580","phase":"PHASE2","title":"Clinical Trial Using the Proteolytic Fraction P1G10 From V. Cundinamarcensis to Heal Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Carlos E Salas","startDate":"2012-08-15","conditions":"Diabetic Foot, Neuropathy, Diabetic, Foot Ulcer","enrollment":50},{"nctId":"NCT02322086","phase":"PHASE2","title":"A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10","status":"COMPLETED","sponsor":"Provectus Pharmaceuticals","startDate":"2015-01","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT01368120","phase":"PHASE1","title":"Antimicrobial Activity of IV Clear™ Dressing - Prevention of Antimicrobial Regrowth","status":"COMPLETED","sponsor":"Covalon Technologies Inc.","startDate":"2011-04","conditions":"Skin Flora Infection","enrollment":37},{"nctId":"NCT02164084","phase":"PHASE1","title":"A 2 Period Cross-over Pharmacokinetic Study of SB204 in Acne Vulgaris","status":"COMPLETED","sponsor":"Novan, Inc.","startDate":"2014-06","conditions":"Acne Vulgaris","enrollment":18},{"nctId":"NCT01065714","phase":"PHASE4","title":"A Study to Investigate the Use of Hydrogel Vehicle in Maintaining the Skin Barrier in Persons With Atopic Dermatitis","status":"COMPLETED","sponsor":"Derm Research, PLLC","startDate":"2010-02","conditions":"Atopic Dermatitis","enrollment":20},{"nctId":"NCT01247818","phase":"PHASE2","title":"Randomized Study of PH-10 for Psoriasis","status":"COMPLETED","sponsor":"Provectus Pharmaceuticals","startDate":"2010-12","conditions":"Psoriasis","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":50,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Hydrogel vehicle","genericName":"Hydrogel vehicle","companyName":"Derm Research, PLLC","companyId":"derm-research-pllc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A hydrogel vehicle serves as an inert pharmaceutical delivery matrix designed to control drug release and improve topical or local drug bioavailability. Used for Topical drug delivery vehicle for dermatological applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}